Central Serous Chorioretinopathy. Central serous chorioretinopathy
Conditions
Interventions
Intervention 1: Intervention group: for patients of treatment group, Eplerenon was initiated. in the first week, 25 mg daily and for the three next weeks, 50 mg daily was administered. Intervention 2:
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Acute onset of disease (less than 3 months) without history of previous treatments including treatment with drugs, PDT, Photocuagulation LASER absence of any pathology and impaired vision in other eye absence of ophthalmic eye pathology such as Glaucoma, Retinal disease and uveitis not taking corticostroids agents normal kidney lab tests for "treatment" group having consent to participating in study
Exclusion criteria
Exclusion criteria: does not having Consent to participating in study Younger than 18 years old suffering from any ocular or kidney disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best Corrected visual aquity. Timepoint: before and one month after initiation of intervention. Method of measurement: snellen chart.;Central macular thickness. Timepoint: before and one month after initiation of intervention. Method of measurement: optical coherence topogrphy.;Macular volume. Timepoint: before and one month after initiation of intervention. Method of measurement: optical coherence topogrphy.;Choroidal thickness. Timepoint: before and one month after initiation of intervention. Method of measurement: optical coherence topogrphy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects of eplerenon. Timepoint: during intervention. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Tohidi
Esfahan University of Medical Sciences
Outcome results
None listed